42nd Annual Meeting of the American-Society-of-Clinical-Oncology Conference

related documents

• A comparison of BRCA1 and BRCA2 risk assessment models.  Conference Paper
• A comparison of patient and physician attributes that promote patient involvement in treatment decision making in the oncology consultation.  Conference Paper
• A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts.  Conference Paper
• A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR plus IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)  Conference Paper
• A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT).  Conference Paper
• A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR plus IFN in the treatment of first-line, poor-prognosis patients with advanced renal cell carcinoma.  Conference Paper
• A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes.  Conference Paper
• A randomized controlled trial to evaluate the impact of an educational DVD an cancer patients considering participation in a phase I clinical trial.  Conference Paper
• Agreement between physicians and patients about what constitutes shared decision making.  Conference Paper
• Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study.  Conference Paper
• Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM.  Conference Paper
• Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study.  Conference Paper
• Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function.  Conference Paper
• Delays in diagnosis and initiating treatment for patients with lung cancer.  Conference Paper
• Dose banding of chemotherapy doses at the Juravinski Cancer Centre.  Conference Paper
• Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease.  Conference Paper
• Effects of adjuvant chemotherapy on the protein C anticoagulant pathway in patients with early stage breast cancer.  Conference Paper
• Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: Stratified by baseline bone alkaline phosphatase (BALP).  Conference Paper
• Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCICCTG MA.14 adjuvant breast cancer trial.  Conference Paper
• Left ventricular function following adjuvant chemotherapy for breast cancer: The NCICCTG MA5 experience.  Conference Paper
• Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer.  Conference Paper
• Misunderstanding of prostate cancer (CaP) among African American (AA) men of lower socioeconomic status (Lo-SES).  Conference Paper
• Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160.  Conference Paper
• NCICCTG MA.17: Tolerability of letrozole among ethnic minority women.  Conference Paper
• Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital.  Conference Paper
• Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP).  Conference Paper
• Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.  Conference Paper
• Phase II trial of preoperative (POP) irinotecan (I) plus cisplatin (C) and radiotherapy for esophageal cancer.  Conference Paper
• Predicting recurrence following post-chemotherapy retroperitoneal lymph node dissection for residual fibrosis or teratoma.  Conference Paper
• Predictors of clinical outcome in patients with bone metastases from prostate cancer.  Conference Paper
• Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5).  Conference Paper
• Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study.  Conference Paper
• Randomized clinical trials in oncology stopped early for benefit (RCTSEB).  Conference Paper
• Understanding and preferences for receiving prognostic information: A comparison of the views of Australian and Canadian patients with metastatic cancer  Conference Paper